ScreenerHero

VCEL Vericel Corporation

NAS · US · Healthcare · Biotechnology · vcel.com
40.74USD+1.72%Mkt Cap: 2.09B $P/E: 88.57

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.09B USD
Enterprise Value1.98B USD
Revenue (TTM)306.30M USD
Gross Profit205.60M USD
Net Income (TTM)16.52M USD
Revenue/Share6.04 USD
Last Price40.74 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees398
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)88.57
P/E (Forward)47.34
PEG—
EV/EBITDA63.60
EV/Revenue6.47
P/S6.70
P/B5.54
EPS (TTM)0.46
EPS (Forward)0.85
52W Range
28.9558% of range49.32
52W High49.32 USD
52W Low28.95 USD
Profitability
Gross Margin74.42%
Oper. Margin0.56%
EBITDA Margin10.17%
Profit Margin5.98%
ROE4.66%
ROA3.39%
Growth
Revenue Growth22.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF51.91M USD
CapEx (TTM)27.16M USD
FCF Margin18.13%
FCF Yield2.66%
Net Debt-69.33M USD
Net Debt/EBITDA-2.23
Balance Sheet
Debt/Equity0.27
Current Ratio5.04
Quick Ratio4.53
Book Value/Sh7.23 USD
Cash/Share3.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateOct 16, 2013
Analyst Consensus
Rating—
Target (Mean)60.57 USD
Upside (mean)+48.7%
Target Range55.00 USD – 72.00 USD
55.00+48.7% to mean72.00
# Analysts7
Ownership
Shares Out.51.21M
Float50.58M
Insiders1.19%
Institutions111.13%
Short Interest
Short Ratio11.0d
Short % Float13.79%
Short % Out.10.71%
Shares Short5.48M
Short (prev mo.)4.72M
Technical
SMA 5041.95 (-2.9%)
SMA 20038.32 (+6.3%)
Beta1.02
S&P 52W Chg16.45%
Avg Vol (30d)506.63K
Avg Vol (10d)519.48K
Technical Indicators
RSI (14)50.2
MACD-0.4431
MACD Signal-0.7273
MACD Hist.+0.2842
BB Upper41.37 USD
BB Middle39.74 USD
BB Lower38.11 USD
BB Width8.20%
ATR (14)1.354 USD
Vol Ratio (20d)1.27x